NeuroSense Therapeutics Announces Availability Of Additional Long-Term Survival Data From PARADIGM Phase 2b Clinical Trial Evaluating PrimeC In Patients With ALS

Neurosense Therapeutics Ltd. +2.82%

Neurosense Therapeutics Ltd.

NRSN

0.73

+2.82%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).

The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in overall survival for patients treated with PrimeC, compared to those initially assigned to placebo.